A5036413377- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 epidemiological studies
- Mental Health Treatment and Access
- Atrial Fibrillation Management and Outcomes
- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Venous Thromboembolism Diagnosis and Management
- Lung Cancer Treatments and Mutations
- Treatment of Major Depression
- Schizophrenia research and treatment
- Political Dynamics in Latin America
- Synthesis and bioactivity of alkaloids
- Bone health and treatments
- Pharmaceutical Economics and Policy
- Gastrointestinal Tumor Research and Treatment
- Economic and Financial Impacts of Cancer
- Social Issues and Policies in Latin America
- Metastasis and carcinoma case studies
- Fibroblast Growth Factor Research
- Cancer Genomics and Diagnostics
Amgen (Switzerland)
2017-2020
Creativ-Ceutical (France)
2014-2018
Annual trivalent influenza vaccines (TIV) containing three strains (A/H1N1, A/H3N2, and one B) have been recommended for the prevention of influenza. However, worldwide co-circulation two distinct B lineages (Victoria Yamagata) difficulties in predicting which lineage will predominate each season led to development quadrivalent (QIV), include both lineages. Our analysis evaluates public health benefit associated influenza-related costs avoided would obtained by using QIV rather than TIV...
Annual trivalent influenza vaccines (TIV) containing 2 A strains and one B lineage have been recommended for the prevention of in most Latin American countries. However, circulation lineages (Victoria Yamagata) difficulties predicting predominating led to development quadrivalent (QIV), including both lineages. Thus, objective was estimate public health impact influenza-related costs if QIV would used instead TIV 3 We a static model over seasons 2010–2014 Brazil, 2007–2014 Colombia 2006–2014...
Little is known about the economic burden of influenza-related hospitalizations in Japan. This study sought to identify factors that contribute total healthcare costs (THCs) associated with due influenza Japanese population.A retrospective cross-sectional database analysis study.A structural equation modelling approach was used analyse a nationwide hospital claims data. included inpatients at least 1 confirmed diagnosis and stay 2 days, who were admitted between April 2014 March 2015.A 5261...
Aim: The approved indication for denosumab (120 mg) was expanded in 2018 to include skeletal-related event (SRE) prevention patients with multiple myeloma (MM). Therefore, a cost-effectiveness analysis conducted comparing zoledronic acid (ZA) SRE MM from the national healthcare system perspective representative sample of European countries: Austria, Belgium, Greece, and Italy. Methods: XGEVA global economic model used calculate incremental ratios (ICERs) vs ZA over lifetime horizon. Clinical...
Background: Venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is the third most common acute cardiovascular disease represents an important burden for patients payers. Objective: The aim was to estimate cost-effectiveness of edoxaban, a non-VKA oral anticoagulant vs. warfarin, currently prescribed treatment VTE in UK. Study design: A Markov model built using data from Hokusai-VTE randomised controlled trial lifetime costs quality-adjusted...
The efficacy of Denosumab in the prevention skeletal-related events multiple myeloma (MM) patients, and its non-inferiority to Zoledronic Acid, was demonstrated a randomized, double blind phase 3 trial (IMW 2017 ASCO 2017). Preliminary analyses survival data suggested that patients treated with may have longer progression free (PFS) compared Acid objective this study quantify potential incremental health benefit associated Denosumab-induced extension PFS, MM patients. Parametric statistical...
63 Background: While no targeted therapy is currently approved for patients with KRAS-mutated mNSCLC, new therapies are being developed KRAS p.G12C-mutated NSCLC. However, real-world evidence on cost of care in managing this population lacking. This study addresses gap by describing costs mNSCLC mutations, stratified LoT and relative to exposure a PD(L)1 inhibitor [PD(L)1i]. Methods: Medicare FFS claims (100% sample, Parts A/B) the PROGNOS NSCLC Explorer dataset were linked identify positive...
278 Background: The number of targeted therapies approved for treatment mNSCLC has increased over the past 5 years. Strategies to identify eligible patients with actionable mutations therapy include simultaneous testing ≥ 2 genes via next generation sequencing (NGS) or multiple gene (MSGT) and sequential single (SSGT). Current clinical practice guidelines strongly recommend broad molecular profiling in all assessment genes, including EGFR, ALK ROS1, that may have potential roles cancer...